COVID-19 in chronic hemodialysis patients: A report of 9 cases in Madrid, Spain.
We describe in depth the clinical, analytical, and radiological details of 9 hemodialysis patients from a single center in Madrid (Spain) diagnosed with COVID-19. Furthermore, we describe and discuss the therapeutic aspects and the patients' outcomes.
DISCUSSION: We present one of the first case series of chronic hemodialysis patients with COVID-19. Between March 14 and April 8, 2020, out of 76 prevalent patients in our hemodialysis unit, 9 (11.8%) patients were diagnosed with COVID-19. The most common symptoms were fever (77.8%), asthenia (77.8%), cough (55.6%), and dyspnea (33.3%). A total of 3 patients developed severe pneumonia, whereas 4 patients developed mild pneumonia. In 2 patients, no pathologic changes were found on chest radiography. All patients presented lymphopenia. While 6 (66.7%) patients required hospitalization, none of them was admitted to intensive care unit. The most common treatments used were azithromycin (100%), hydroxychloroquine (66.7%), lopinavir/ritonavir (55.6%) and β-interferon (22.2%). In general, we observed a mild to moderate severity of disease in our case series. One patient died, however due to a cause not related to COVID-19.
PMID: 33155542 [PubMed - as supplied by publisher]
Source: Clinical Nephrology - Category: Urology & Nephrology Authors: de la Flor Merino JC, Valga Amado F, Marschall A, Linares Grávalos T, Canepa-Escaro F, Ruiz Cícero E, Albarracín Sierra C, Gallegos Bayas G, Rodeles Del Pozo M Tags: Clin Nephrol Source Type: research
More News: Azithromycin | China Health | Coronavirus | Cough | COVID-19 | Dialysis | Hemodialysis | Hydroxychloroquine | Intensive Care | Kaletra | Norvir | Pneumonia | Radiography | Respiratory Medicine | Spain Health | Urology & Nephrology | Zithromax